Biolidics Limited (Formerly known as Clearbridge BioMedics)

Biolidics Limited, based in Singapore, is a precision medicine medical technology company founded in 2009. The company specializes in developing innovative diagnostic solutions that aim to reduce healthcare costs and enhance clinical outcomes. Biolidics is publicly listed on the Singapore Stock Exchange and has a global presence, operating in regions such as Japan, China, Europe, the United States, and Southeast Asia. The flagship product of Biolidics is the ClearCell® FX1 System, an automated in vitro diagnostic device that utilizes patented microfluidic biochip technology to separate and enrich circulating tumor cells from blood samples. This label-free system preserves the viability of cancer cells for further analysis, supporting non-invasive cancer diagnostics. Biolidics also offers diagnostic tools for infectious diseases and provides laboratory testing services, contributing significantly to its revenue. Additionally, the company is exploring technology-enabled lifestyle businesses, including multi-channel networks and social e-commerce platforms, to diversify its revenue streams.

• Employees16
• Founded2009
• Annual Revenue$928000
• Total Funding$4822566